SUBSCRIBE
SUBSCRIBE
News   Drug Development

Merck & Co., Inc. Restarts Cholesterol Race Four Years After Pfizer Inc. Failure

November 10, 2010 | 
1 min read
Bloomberg -- Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels.
Clinical research Phase III
Merck & Co. Pfizer
MORE ON THIS TOPIC
halftone magazine style banner, dislike, negative rating, hand thumbs down
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
September 4, 2025
 · 
1 min read
 · 
Lori Ellis
Sea wave. Hand drawn realistic vector illustration in oriental vintage ukiyo-e style.
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
September 3, 2025
 · 
2 min read
 · 
Tristan Manalac